Benefits versus harm of intraoperative glucocorticoid for postoperative nausea and vomiting prophylaxis

Br J Anaesth. 2023 Jul;131(1):8-10. doi: 10.1016/j.bja.2023.04.013. Epub 2023 May 12.

Abstract

Intraoperative use of glucocorticoids is effective for postoperative nausea and vomiting prophylaxis and can also provide early postoperative analgesic effects, but the consequences for chronic post-surgical pain are debatable. In a secondary analysis of the large pragmatic Perioperative Administration of Dexamethasone and Infection trial (n=8478), the primary outcome of pain at the surgical wound at 6 months after surgery was increased in subjects receiving dexamethasone 8 mg i.v. for postoperative nausea and vomiting prophylaxis, a dose not associated with the detrimental effect of surgical site infection in the original study. In contrast, a more detailed assessment of chronic post-surgical pain after exclusion of patients with preoperative pain at the surgical site showed no differences with or without intraoperative dexamethasone regarding chronic post-surgical pain characteristics (intensity and neuropathic features). Because of several confounding factors especially regarding surgical details, these unexpected findings call for more well-designed studies about the potential risk of intraoperative treatments, such as glucocorticoids, on late post-surgical pain.

Keywords: PADDI trial; chronic post-surgical pain; dexamethasone; glucocorticoids; postoperative pain; postoperative recovery; wound pain.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antiemetics* / therapeutic use
  • Dexamethasone / therapeutic use
  • Glucocorticoids* / therapeutic use
  • Humans
  • Pain, Postoperative / drug therapy
  • Pain, Postoperative / prevention & control
  • Postoperative Nausea and Vomiting / complications
  • Surgical Wound Infection / drug therapy

Substances

  • Glucocorticoids
  • Dexamethasone
  • Antiemetics